P-166 Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
Year: 2023
Type: conference-abstract
Authors: Carlyn Rose Tan, Kylee Maclachlan, David Nemirovsky, Andriy Derkach, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Dhwani Patel, Tala Shekarkhand, Colin Rueda, Oscar Lahoud, Gunjan Shah, Michael Scordo, David Chung, Heather Landau, Sergio Giralt, Saad Usmani, Alexander Lesokhin, Neha Korde
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4387003733